Editor’s Take
Eli Lilly has made significant strides in U.S. investments this past year, including:
- In January, it chose Lehigh Valley, Pennsylvania for a new manufacturing site.
- In May, Lilly announced an additional $4.5 billion investment across two Indiana locations.
In a recent development, Resilience and Eli Lilly will invest $750 million to expand Resilience’s advanced manufacturing operations in the Cincinnati, Ohio region. This expansion will include the production of Lilly’s KwikPen injectable device for diabetes and obesity medications.
Key Highlights:
- The addition of KwikPen production is expected to create at least 400 new high-skilled jobs, raising the total of Resilience-created jobs in Ohio to over 1,400.
- Site preparation for the expansion is currently underway, with full operations slated to begin in early 2027.
William S. Marth, President and CEO of Resilience, stated:
“We are proud of what we have built together with Lilly… This new expansion reflects our commitment to advanced sterile injectable and device assembly operations in the U.S.”
Edgardo Hernandez, Lilly’s EVP and President of Manufacturing Operations, emphasized:
“As demand for our medicines grows, having strong partners like Resilience is critical for scaling our manufacturing capabilities.”
The partnership between Lilly and Resilience has already led to the production of over 150 million doses of medicines in the U.S., establishing one of the largest sterile injectable manufacturing operations in the country.
